Avrobio (NASDAQ:AVRO) issued its quarterly earnings data on Monday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.01), MarketWatch Earnings reports.
NASDAQ:AVRO opened at $19.16 on Tuesday. Avrobio has a twelve month low of $11.85 and a twelve month high of $53.70. The stock has a market capitalization of $461.72 million and a price-to-earnings ratio of -5.29.
A number of analysts recently issued reports on the company. Cowen reissued a “buy” rating on shares of Avrobio in a report on Tuesday. Janney Montgomery Scott started coverage on Avrobio in a report on Friday, April 5th. They set a “buy” rating and a $24.42 price objective on the stock. HC Wainwright set a $40.00 price target on Avrobio and gave the company a “buy” rating in a report on Tuesday, March 26th. Zacks Investment Research cut Avrobio from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. Finally, Leerink Swann lowered their price target on Avrobio from $27.00 to $19.00 and set a “market perform” rating on the stock in a report on Thursday, January 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. Avrobio presently has a consensus rating of “Buy” and an average target price of $31.06.
A hedge fund recently raised its stake in Avrobio stock. Geode Capital Management LLC raised its holdings in Avrobio Inc (NASDAQ:AVRO) by 31.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 86,217 shares of the company’s stock after buying an additional 20,744 shares during the quarter. Geode Capital Management LLC owned about 0.36% of Avrobio worth $1,435,000 at the end of the most recent quarter. Institutional investors and hedge funds own 69.11% of the company’s stock.
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Featured Story: Derivative
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.